Pacira生物科学 PCRX 深 沪
已收盘 05-22 16:00:00 美东时间
23.35
-0.130
-0.55%
华盛通- 最 高23.74
- 今 开23.50
- 成交量 85.79万股
- 最 低 23.24
- 昨 收 23.48
- 总市值 9.19亿
- 52周最高 27.64
- 市盈率 静 149.49
- 换手率 2.18%
- 52周最低 18.80
- 委 比 59.40%
- 总股本 3934.79万
- 历史最高 121.95
- 量 比 1.99
- 振 幅 2.13%
- 历史最低 6.51
- 每 手 1
- 风险率 1.80%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Pacira shareholders lobbied by hedge fund board nominees
Shareholders of Pacira BioSciences (PCRA) have been told by two individuals backed by DOMA Perpetual Capital Management to join the biopharma's board to ignore criticisms of them by management and ele...
05-22 02:41
A LETTER TO PACIRA BIOSCIENCES SHAREHOLDERS FROM DOMA PERPETUAL CAPITAL MANAGEMENT LLC
FRANK LEE AND THE BOARD HAVE OVERSEEN GROSS AND PERSISTENT UNDERPERFORMANCE FOR YEARS. WHY WOULD SHAREHOLDERS VOTE TO CONTINUE THIS UNRELENTING LACK OF TOTAL RETURN TO SHAREHOLDERS ("TRS"), ...
05-22 01:53
DOMA Perpetual Director Nominees Send Letter to Shareholders of Pacira Biosciences
Independent Directors, Christopher Dennis, MD, MBA, FAPA and Oliver Benton "Ben" Curtis III Outline How Their Skills and Experience Will Drive Positive Change Intend to Work Collaboratively ...
05-21 00:28
Pacira BioSciences Files Investor Presentation Highlighting Successful Execution of its Long-Term Strategy to Drive Value for All Stockholders
Pacira BioSciences urges stockholders to vote "FOR" the election of its nominees on the BLUE proxy card for the 2026 Annual Meeting. The company highlights its 5x30 strategy, delivering record financial performance in 2025 with $726.4M revenue, 79.4% GAAP gross margin, and 81.2% non-GAAP gross margin. It emphasizes disciplined capital allocation, a strong board with deep expertise, and superior nominees compared to DOMA Perpetual's underqualified...
05-20 10:30
Pacira BioSciences Sends Letter to Stockholders Reiterating Superior Qualifications of its Board Nominees
Pacira BioSciences urges stockholders to vote "FOR" its three highly qualified director nominees—Christopher Christie, Samit Hirawat, MD, and Thomas Wiggans—on the BLUE proxy card for the 2026 Annual Meeting. The company highlights the nominees' extensive experience in healthcare, biopharmaceuticals, and leadership, aligning with Pacira's 5x30 strategy for sustainable growth. In contrast, Pacira criticizes DOMA's nominees for lacking industry exp...
05-12 20:01
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pacira BioSciences, Inc. granted inducement awards to ten new employees on May 4, 2026, under its 2014 Inducement Plan, approved by the People & Compensation Committee without stockholder approval. Three employees received stock options for 36,800 shares, and ten received restricted stock units for 27,700 shares. The stock options have a 10-year term, a four-year vesting schedule, and an exercise price of $24.69 per share. The restricted stock un...
05-08 12:00
美股大行评级 | 苹果获多家机构上调目标价，最高至335美元；闪迪获华尔街大行看多至2000美元
今日重点评级关注：Benchmark：维持史密斯微软件"买入"评级，目标价从2美元升至2.5美元；Citizens：维持DBV Technologies"跑赢大市"评级，目标价从47美元升至55美元
05-04 16:04
Needham Maintains Buy on Pacira BioSciences, Raises Price Target to $32
Needham analyst Serge Belanger maintains Pacira BioSciences (NASDAQ:PCRX) with a Buy and raises the price target from $30 to $32.
05-01 19:22
Pacira BioSciences Q1 2026 Earnings Call Transcript
On Thursday, Pacira BioSciences (NASDAQ:PCRX) discussed first-quarter financial...
05-01 05:27
Pacira BioSciences Affirms FY2026 Sales Guidance of $745.000M-$770.000M vs $759.317M Est
Pacira BioSciences, Inc.___________________________ Summary of 2026 Financial Guidance(dollars in millions)2026 Financial GuidanceAmountEXPAREL net product sales$600 to $620Total revenues$745 to $770Non-GAAP gross
05-01 04:02
